Daniel Tsai (@DanielHTTsai) profile picture

Research Fellow | Pharmacoepidemiology, comparative effectiveness research, AsPEN, NeuroGEN

London, England
Joined August 2022
Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)Photo by Daniel Tsai (@DanielHTTsai)
"A publicly accessible metadata of the 15 databases available to NeuroGEN researchers across North America, Europe, Asia, Oceania to facilitate the RWD use for assessment of disease burden and development of current and future treatments for neurological and mental disorders."
2
5
7
690
Daniel Tsai retweeted
Our study published in @LancetRH_WPac analyzed post-COVID-19 #sequelae across Asia–Pacific populations, revealing diverse short-term multi-organ #complications and elevated #mortality, especially in patients aged >65 or with #multimorbidity, emphasizing the need for targeted monitoring and #reinfection prevention. Our paper: sciencedirect.com/science/ar… The team: @Ranzhang_hku @IVANCHLAM @Yi_Chai18 of @ShenzhenUni Xinyi Liu @_GeorgeTan & @jenni_ilomaki & Professor J. Simon Bell of @CentMedUseSafet @MonashPharm Daniel Hsiang-Te Tsai & Prof. Edward Chia-Cheng Lai & Chin-Yao Shen & Michael Chun-Yuan Cheng of @NCKU_official Prof. Jeff Harrison & @amyhychan of @FMHS_UoA Dr. Bin Hong of @skku_official Prof. Ju-Young Shin of @SNU_Pharm @SeoulNatlUni Dr. Shahab Abtahi & @OKlungel of @UUUIPS @UniUtrecht @ChuiCeline @snowly12191 @Esther_CSMPRHKU @hkumed @HKU_FMPC @HkuPharm @CSMPR_HKUPharm #HKU #HKUMed #FMPC #PrimaryCare #HKUPharm #CSMPR #COVID19 #PostCOVID #RetrospectiveCohort #PropensityScore #ElectronicMedicalRecord #EMR
23
17
416
Talking about CCW during educational session this ACPE. Always find something new when I approach this methodology every time.
1
1
36
Cyberport park is so romantic. The sunset is just breathtaking.
1
1
34
New in #ASNKidney360: SGLT2 inhibitors were associated with lower nephrolithiasis risk compared to DPP4i and GLP-1RA in patients with diabetes. Read more: kidney.pub/KID0981
7
16
2,138
No significant difference in IBD risk between SGLT2i vs DPP4i Null results are just as essential, they refine expectations, guide better science, and prevent overhype. authors.elsevier.com/c/1lqE7…
1
1
1
34
Happy to get this piece published. A hard work emulating three trials to inform drug repurposing. @Lai_Edw @albert_ch1210 #PHDCenter
SGLT2 inhibitors and chronic kidney disease: SGLT2 inhibitors may be considered to reduce risk of chronic kidney disease mineral and bone disorders (CKD-MBD) in patients with type  2 diabetes mellitus and stage 1–3 CKD. ➡️ cmaj.ca/lookup/doi/10.1503/c…
1
1
4
257
We found that antipsychotic augmentation was associated with a reduced incidence of suicide attempt. However, after using the clone-censor-weight approach to control for time-lag bias, we no longer found any association of antipsychotic augmentation with reduced risks of suicide.
1
2
3
464
Daniel Tsai retweeted
We’re analyzing (early teaser) where the U.S. really gets its final drug dosages from—and early data is eye-opening. This is why drug supply chains must be protected from strain—including #tariffs. Global thinking is essential here.
1
2
5
275